Information about sponsored clinical trials and result information are provided for informational purposes only and are not intended to promote any product or use. Clinical study results are intended to report the results of the study that were known at the time of the study's completion. The results therefore do not provide a comprehensive and current review of the safety and efficacy of any drug based upon all information available. Physicians and patients should refer to the current approved product labeling for information on approved indications in their country.
This information is not intended to replace the advice of a health care professional. Only a physician can determine if a specific medicine is the correct or best treatment option for a particular patient. If you have questions, please consult a health care professional.

A - B - C - D - E - F - G - H I - J - K - L - M N - O - P - Q - R - S T - U - V - W - X - Y - Z

Clinical study results Sanofi pharma, including Sanofi Genzyme – Letter E

GENERIC NAME

TRADE NAME

CONDITION

STUDY CODE

STUDY NAME

ACCESS TO STUDY / PROTOCOL

ACCESS TO RESULTS

EFTRENONACOG ALFA

Alprolix

Hemophilia B

EFC16227 (998HB303)

NA

NCT02234310

ELIGLUSTAT TARTRATE

Cerdelga

Gaucher Disease

ACC14373

NA

NCT02422654

ELIGLUSTAT TARTRATE

Cerdelga

Gaucher Disease

GZGD00304

NA

NCT00358150

ELIGLUSTAT TARTRATE

Cerdelga

Gaucher Disease

GZGD02507

ENGAGE

NCT00891202

ELIGLUSTAT TARTRATE

Cerdelga

Gaucher Disease

GZGD02607

ENCORE

NCT00943111

ELIGLUSTAT TARTRATE

Cerdelga

Gaucher Disease

GZGD03109

EDGE

NCT01074944

ELIGLUSTAT TARTRATE

Cerdelga

Gaucher Disease

POP13777

NA

NCT02536911

ELIGLUSTAT TARTRATE

Cerdelga

Gaucher Disease

POP13778

NA

NCT02536937

ENOXAPARIN SODIUM

Lovenox

Thromboprophylaxis

EFC10094

NA

NCT00723216

ENOXAPARIN SODIUM

Lovenox

Myocardial Infarction, Acute

EFC6147

EXTRACT

NCT00077792

ENOXAPARIN SODIUM

Lovenox

Prevention VTE in Orthopaedic Surgery

EFC6770

NA

NCT00349180

ENOXAPARIN SODIUM

Lovenox

Myocardial Infarction, Non-ST-Segment Elevation Angina, Unstable

ENO_GMA_301

SYNERGY

NCT00043784

ENOXAPARIN SODIUM

Lovenox

Acute Illness

ENOXA_C_01249

LIFENOX

NCT00622648

ENOXAPARIN SODIUM

Lovenox

Thrombosis

ENOXA_C_02537

NA

NCT00622115

ENOXAPARIN SODIUM

Lovenox

Prevention VTE in Orthopaedic Surgery

SFY6771

NA

NCT00685958

ENOXAPARIN SODIUM

Lovenox

Percutaneous Coronary Intervention

XRP4563_4001

STEEPLE

NCT00077844

ENOXAPARIN SODIUM

Lovenox

Renal Dialysis

ENOXA_L_00821

HENOX

NCT00347490

ENOXAPARIN SODIUM

Lovenox

Thromboembolism, Venous (VTE)

XRP4563A_4001

TROMBOTEK

NCT00265993

ENOXAPARIN SODIUM

Lovenox

Cardiovascular Diseases

XRP4563B_4001

RESCUE

NCT00077818

ENOXAPARIN SODIUM

Lovenox

Medical Prevention Therapy

XRP4563C_3501

EXCLAIM

NCT00077753

ENOXAPARIN SODIUM

Lovenox

Cardiovascular Diseases

XRP4563H_4001

PREVAIL

NCT00077805

EPLIVANSERIN

Not marketed

Pain, Sleep Disorders, Fibromyalgia

ACT5400

NA

NCT00313885

EPLIVANSERIN

Not marketed

Sleep disorders

EFC10480

DREAMS

EudraCT: 2007-003822-28

EPLIVANSERIN

Not marketed

Insomnia

EFC10844

ECLIPSE

EudraCT: 2008-003791-22

EPLIVANSERIN

Not marketed

Sleep disorders

EFC6220

EPOCH

NCT00308503

EPLIVANSERIN

Not marketed

Sleep disorders

LTE6217

GEMS

EudraCT: 2005-003080-23

EPLIVANSERIN

Not marketed

Sleep disorders

LTE6262

EPLILONG

EudraCT: 2005-003082-16

EPLIVANSERIN

Not marketed

Sleep disorders

PKD10491

PKiDs

NCT00913614

References:
*These study results were previously posted on GenzymeClinicalResearch.com
**This link replaces the same summary that was previously posted